Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Cogent Biosciences (COGT) Equity Ratio (2017 - 2021)

Cogent Biosciences has reported Equity Ratio over the past 5 years, most recently at 0.92 for Q3 2021.

  • Quarterly results put Equity Ratio at 0.92 for Q3 2021, up 677.64% from a year ago — trailing twelve months through Sep 2021 was 0.92 (up 677.64% YoY), and the annual figure for FY2020 was 0.94, up 45.53%.
  • Equity Ratio for Q3 2021 was 0.92 at Cogent Biosciences, down from 0.93 in the prior quarter.
  • Over the last five years, Equity Ratio for COGT hit a ceiling of 0.95 in Q1 2021 and a floor of 1.41 in Q1 2018.
  • Median Equity Ratio over the past 5 years was 0.65 (2020), compared with a mean of 0.43.
  • Biggest five-year swings in Equity Ratio: plummeted 132.06% in 2020 and later skyrocketed 677.64% in 2021.
  • Cogent Biosciences' Equity Ratio stood at 0.99 in 2017, then soared by 170.49% to 0.7 in 2018, then dropped by 8.32% to 0.64 in 2019, then surged by 45.53% to 0.94 in 2020, then fell by 2.08% to 0.92 in 2021.
  • The last three reported values for Equity Ratio were 0.92 (Q3 2021), 0.93 (Q2 2021), and 0.95 (Q1 2021) per Business Quant data.